News | January 05, 2023
Yaral Pharma launches diclofenac epolamine topical system 1.3%
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
Miravo to remain a Canadian controlled and operated company following closing of the transaction
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
The company will set-up a pharmaceuticals formulation manufacturing unit with an investment of Rs. 100 crore in Odisha
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
The company has successfully developed Methyl salicylate using Flow Chemistry and successfully erected a Flow reactor at Jhagadia plant and expects to start production from Q3 FY23
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Subscribe To Our Newsletter & Stay Updated
